-
Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
Toxicology 20171201
-
Dexrazoxane Averts Idarubicin-Evoked Genomic Damage by Regulating Gene Expression Profiling Associated With the DNA Damage-Signaling Pathway in BALB/c Mice.
Toxicological sciences : an official journal of the Society of Toxicology 20171101
-
Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice.
Toxicology and applied pharmacology 20160315
-
Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Toxicology 20130915
-
Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.
Pediatric blood & cancer 20121215
-
Use of the cardioprotectants thymosin β4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double-blind, clinical trial.
Annals of the New York Academy of Sciences 20121001
-
BET 3: emergency management of anthracycline extravasation.
Emergency medicine journal : EMJ 20120901
-
Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts.
Canadian journal of physiology and pharmacology 20120901
-
Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
Current pharmaceutical biotechnology 20120801
-
Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients.
American journal of hematology 20120801
-
Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.
Translational oncology 20120801
-
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120710
-
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Future cardiology 20120701
-
Chemotherapy-induced cardiotoxicity.
Current heart failure reports 20120601
-
Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training.
American journal of physiology. Heart and circulatory physiology 20120515
-
Savene® (dexrazoxane) use in clinical practice.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20120501
-
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120401
-
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity.
Canadian journal of physiology and pharmacology 20120401
-
Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells.
Biology of reproduction 20120301
-
Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation.
International journal of cardiology 20120209
-
Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
Cancer chemotherapy and pharmacology 20120201
-
Dexrazoxane treatment of doxorubicin extravasation injury in four dogs.
Journal of the American Veterinary Medical Association 20120201
-
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.
Nature 20120112
-
Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment.
Anti-cancer drugs 20120101
-
Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies.
Biochemistry research international 20120101
-
Strain echocardiography in early detection of Doxorubicin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.
ISRN pediatrics 20120101
-
Cardioprotective effect of methanolic extract of Ixora coccinea Linn. leaves on doxorubicin-induced cardiac toxicity in rats.
Indian journal of pharmacology 20120101
-
Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma.
Clinical sarcoma research 20120101
-
Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats.
Oxidative medicine and cellular longevity 20120101
-
A low dose of doxorubicin improves antioxidant defence system and modulates anaerobic metabolism during the development of lymphoma.
Indian journal of pharmacology 20120101
-
Targeted therapies in sarcomas: challenging the challenge.
Sarcoma 20120101
-
Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
PloS one 20120101
-
Prevention and treatment of doxorubicin-induced cardiotoxicity by dexrazoxane and schisandrin B in rabbits.
International journal of toxicology 20111201
-
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology 20111201
-
Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.
Toxicology 20111118
-
Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.
Hematology reports 20111028
-
Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma.
Hematology reports 20111028
-
SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly.
Hematology reports 20111028
-
Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis.
International journal of cardiology 20111020
-
Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity.
Cell death & disease 20110801
-
Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells.
Mutagenesis 20110701
-
Cardioprotective interventions for cancer patients receiving anthracyclines.
The Cochrane database of systematic reviews 20110615
-
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
European journal of cancer (Oxford, England : 1990) 20110601
-
Mechanisms and management of doxorubicin cardiotoxicity.
Herz 20110601
-
Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Journal of clinical pharmacology 20110501
-
Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
British journal of pharmacology 20110501
-
Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
Pediatric cardiology 20110301
-
[Extravasation of cytostatic drugs].
Magyar onkologia 20110301
-
Extravasation management: clinical update.
Seminars in oncology nursing 20110201
-
Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites--the cardioprotectant dexrazoxane as a model case.
Journal of chromatography. A 20110121
-
Should anthracyclines and dexrazoxane be used for children with cancer?
The Lancet. Oncology 20110101
-
Cardiac function in long-term survivors of childhood lymphoma.
Cardiology research and practice 20110101
-
Cardiovascular effects in childhood cancer survivors treated with anthracyclines.
Cardiology research and practice 20110101
-
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
Journal of experimental & clinical cancer research : CR 20110101
-
Review of cardiotoxicity in pediatric cancer patients: during and after therapy.
Cardiology research and practice 20110101
-
Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes.
PloS one 20110101
-
An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection.
Photochemistry and photobiology 20110101
-
An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.
PloS one 20110101
-
Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan.
Oxidative medicine and cellular longevity 20110101
-
Evaluation of chromosomal instability in diabetic rats treated with naringin.
Oxidative medicine and cellular longevity 20110101
-
Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27.
PloS one 20110101
-
[Cardiotoxicity of conservative treatment of solid tumors].
Likars'ka sprava 20110101
-
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
Veterinary and comparative oncology 20101201
-
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
Current oncology reports 20101101
-
Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
The oncologist 20101101
-
Scavenging effects of dexrazoxane on free radicals.
Journal of clinical biochemistry and nutrition 20101101
-
Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
Pediatric hematology and oncology 20101001
-
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
The Lancet. Oncology 20101001
-
Cardiac side-effects of cancer chemotherapy.
International journal of cardiology 20100924
-
Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin.
Anti-cancer drugs 20100901
-
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Journal of Korean medical science 20100901
-
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats.
Cancer chemotherapy and pharmacology 20100701
-
Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
The Annals of pharmacotherapy 20100501
-
The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Journal of pediatric hematology/oncology 20100501
-
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20100401
-
Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib.
Cardiovascular toxicology 20100301
-
[Extra- and paravasation of cytotoxic drugs. Pathomechanisms and current preventive measures].
Medizinische Monatsschrift fur Pharmazeuten 20100301
-
A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Toxicology 20100227
-
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).
Leukemia 20100201
-
Naproxen aggravates doxorubicin-induced cardiomyopathy in rats.
Indian journal of pharmacology 20100201
-
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
Journal of the National Cancer Institute 20100106
-
Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).
British journal of pharmacology 20100101
-
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
The Journal of pharmacology and experimental therapeutics 20100101
-
Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro.
Oncology reports 20100101
-
Antimuscarinic action of doxorubicin does not involve free-radical formation in isolated guinea pig hearts.
Canadian journal of physiology and pharmacology 20100101
-
Drugs and pharmaceuticals: management of intoxication and antidotes.
EXS 20100101
-
[Schisandrin B prevents doxorubicin-induced cardiotoxicity in rabbits].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100101
-
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Molecular cancer 20100101
-
Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer.
Oncology 20100101
-
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
BMC cancer 20100101
-
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Nederlands tijdschrift voor geneeskunde 20100101
-
Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Progress in cardiovascular diseases 20100101
-
Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation.
PloS one 20100101
-
Chemotherapy in Ewing's sarcoma.
Indian journal of orthopaedics 20100101
-
Clinical trials and progress with paclitaxel in ovarian cancer.
International journal of women's health 20100101
-
Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
Journal of cancer research and therapeutics 20100101
-
Treatment of cancer in the older aged person.
Mediterranean journal of hematology and infectious diseases 20100101
-
Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis.
Multiple sclerosis international 20100101
-
Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.
British journal of cancer 20090915
-
Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane.
Cancer chemotherapy and pharmacology 20090901
-
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
British journal of cancer 20090901
-
Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice.
Naunyn-Schmiedeberg's archives of pharmacology 20090701
-
The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Journal of inorganic biochemistry 20090701
-
Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine.
Cardiovascular toxicology 20090601
-
Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
Molecular cancer therapeutics 20090501
-
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management.
Journal of clinical medicine research 20090401
-
Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide.
Prescrire international 20090201
-
Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Cancer chemotherapy and pharmacology 20090101
-
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090101
-
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.
BMC medical genomics 20090101
-
Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
Pharmacological reports : PR 20090101
-
N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes.
BMC pharmacology 20090101
-
Primary Adult Renal Ewing's Sarcoma: A Rare Entity.
Sarcoma 20090101
-
Anthracycline extravasation injuries: management with dexrazoxane.
Therapeutics and clinical risk management 20090101
-
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.
BMJ (Clinical research ed.) 20090101
-
In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening.
Current chemical genomics 20090101
-
QTc prolongation assessment in anticancer drug development: clinical and methodological issues.
Ecancermedicalscience 20090101
-
Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.
Molecular pharmacology 20081201
-
Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Breast cancer research and treatment 20081201
-
A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
Journal of Korean medical science 20081201
-
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Expert review of cardiovascular therapy 20081101
-
Dexrazoxane treatment for intrathoracic anthracycline extravasation.
Onkologie 20081101
-
Dexrazoxane: a second look. Prevention of anthracycline cardiotoxicity: useful for some patients.
Prescrire international 20081001
-
The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.
Drug metabolism and disposition: the biological fate of chemicals 20080901
-
Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.
The European respiratory journal 20080801
-
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
The Journal of pharmacology and experimental therapeutics 20080701
-
Systemic treatments for mesothelioma: standard and novel.
Current treatment options in oncology 20080601
-
Cardioprotective interventions for cancer patients receiving anthracyclines.
The Cochrane database of systematic reviews 20080416
-
Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.
The oncologist 20080401
-
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Molecular pharmacology 20080301
-
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301
-
[The significance of extravasation in oncological care].
Magyar onkologia 20080301
-
The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Expert opinion on investigational drugs 20080201
-
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
Current oncology (Toronto, Ont.) 20080101
-
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
Hemoglobin 20080101
-
Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor.
Sarcoma 20080101
-
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
American journal of cardiovascular drugs : drugs, devices, and other interventions 20080101
-
Aqueous fish extract increases survival in the mouse model of cytostatic toxicity.
Journal of experimental & clinical cancer research : CR 20080101
-
Effect of dexrazoxane and amifostine on the vertebral bone quality of Doxorubicin treated male rats.
The open orthopaedics journal 20080101
-
Extravasational side effects of cytotoxic drugs: A preventable catastrophe.
Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India 20080101
-
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Experimental biology and medicine (Maywood, N.J.) 20071201
-
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
International journal of nanomedicine 20071201
-
Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?
European journal of pediatrics 20071101
-
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
British journal of cancer 20071022
-
Re: Totect: a new agent for treating anthracycline extravasation.
Clinical journal of oncology nursing 20071001
-
Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Cancer research 20070915
-
Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review.
European journal of cancer (Oxford, England : 1990) 20070901
-
Do antioxidants interfere with radiation therapy for cancer?
Integrative cancer therapies 20070901
-
Extravasation management.
Seminars in oncology nursing 20070801
-
Dexrazoxane for anthracycline extravasation.
Expert review of anticancer therapy 20070801
-
[Chemotherapeutics-induced heart failure].
Medizinische Klinik (Munich, Germany : 1983) 20070715
-
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
British journal of pharmacology 20070701
-
Management of anthracycline extravasation injuries.
The Annals of pharmacotherapy 20070701
-
Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Health technology assessment (Winchester, England) 20070701
-
Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity.
British journal of cancer 20070604
-
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Expert opinion on pharmacotherapy 20070601
-
Totect: a new agent for treating anthracycline extravasation.
Clinical journal of oncology nursing 20070601
-
Nanoparticles in modern medicine: state of the art and future challenges.
International journal of nanomedicine 20070601
-
Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
European journal of cancer (Oxford, England : 1990) 20070501
-
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070420
-
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
Annals of oncology : official journal of the European Society for Medical Oncology 20070301
-
Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.
British journal of cancer 20070212
-
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070210
-
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
Blood 20070201
-
Long-term effects of treatments for childhood cancers.
Current opinion in pediatrics 20070201
-
Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
British journal of cancer 20070129
-
Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Cell biology and toxicology 20070101
-
Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.
Alternative therapies in health and medicine 20070101
-
Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2.
Alternative therapies in health and medicine 20070101
-
Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents.
Physiological research 20070101
-
Molecular and cellular mechanisms of anthracycline cardiotoxicity.
Cardiovascular toxicology 20070101
-
Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Cardiovascular toxicology 20070101
-
Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Cardiovascular toxicology 20070101
-
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Cardiovascular toxicology 20070101
-
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Cardiovascular toxicology 20070101
-
Treatment of doxorubicin extravasation with intravenous dexrazoxane in a cat.
Journal of veterinary internal medicine 20070101
-
Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
Pathology oncology research : POR 20070101
-
Antivasoconstrictor effect of the neuroprotective agent dexrazoxane in rat aorta.
Life sciences 20061214
-
Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
British journal of pharmacology 20061201
-
Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.
International journal of clinical oncology 20061201
-
Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.
Arquivos brasileiros de cardiologia 20061201
-
Anthracycline cardiotoxicity.
Expert opinion on drug safety 20061101
-
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cancer chemotherapy and pharmacology 20061001
-
Dexrazoxane prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart.
Cardiovascular drugs and therapy 20061001
-
A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.
British journal of cancer 20060904
-
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
International journal of radiation oncology, biology, physics 20060715
-
Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
Onkologie 20060701
-
Exposure to anthracyclines during childhood causes cardiac injury.
Seminars in oncology 20060601
-
Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Seminars in oncology 20060601
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20060601
-
Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Circulation 20060509
-
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology 20060401
-
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.
Cardiovascular research 20060215
-
Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Toxicology letters 20060208
-
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060201
-
Altered responsiveness of the guinea-pig isolated ileum to smooth muscle stimulants and to electrical stimulation after in situ ischemia.
British journal of pharmacology 20060201
-
Anticancer agents and cardiotoxicity.
Seminars in oncology 20060201
-
Extravasation of chemotherapeutic agents: prevention and treatment.
Seminars in oncology 20060201
-
Dexrazoxane use in the prevention of anthracycline extravasation injury.
Future oncology (London, England) 20060201
-
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
Cancer chemotherapy and pharmacology 20060101
-
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Annals of neurology 20060101
-
[Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
Magyar onkologia 20060101
-
Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma.
BMC cancer 20060101
-
The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane.
Sarcoma 20060101
-
[Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Postepy higieny i medycyny doswiadczalnej (Online) 20060101
-
Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
Pediatric blood & cancer 20051201
-
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051201
-
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
European journal of pediatrics 20051101
-
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001
-
Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20050915
-
Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Drug metabolism and disposition: the biological fate of chemicals 20050901
-
Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.
Calcified tissue international 20050901
-
Molecular pharmacology of the interaction of anthracyclines with iron.
Molecular pharmacology 20050801
-
CD95/Apo-1/Fas: independent cell death induced by doxorubicin in normal cultured cardiomyocytes.
Cancer immunology, immunotherapy : CII 20050701
-
Monitoring cardiac function in patients receiving doxorubicin.
Seminars in nuclear medicine 20050701
-
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Pediatric blood & cancer 20050615
-
Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
Drug metabolism and disposition: the biological fate of chemicals 20050601
-
Prediction of genotoxicity of chemical compounds by statistical learning methods.
Chemical research in toxicology 20050601
-
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 20050515
-
Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20050401
-
Gender-dependent reductions in vertebrae length, bone mineral density and content by doxorubicin are not reduced by dexrazoxane in young rats: effect on growth plate and intervertebral discs.
Calcified tissue international 20050301
-
Cardioprotective interventions for cancer patients receiving anthracyclines.
The Cochrane database of systematic reviews 20050125
-
The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Anti-cancer drugs 20050101
-
Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Paediatric drugs 20050101
-
Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Drugs 20050101
-
The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.
American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101
-
Clinical nurse specialist and evidence-based practice: managing anthracycline extravasation.
Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses 20050101
-
Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin's Lymphoma.
Clinical drug investigation 20050101
-
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Neurology 20041228
-
The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
Journal of inorganic biochemistry 20041101
-
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Cancer treatment reviews 20041101
-
[Cardiac prevention: the oncologic point of view].
Bulletin du cancer 20041101
-
Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Nature clinical practice. Oncology 20041101
-
Accelerated approval of oncology products: a decade of experience.
Journal of the National Cancer Institute 20041020
-
Concurrent therapies that protect against doxorubicin-induced cardiomyopathy.
Clinical journal of oncology nursing 20041001
-
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Cancer chemotherapy and pharmacology 20040901
-
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
The New England journal of medicine 20040708
-
Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
European journal of heart failure 20040601
-
[Dexrazoxane and cardiotoxicity in repeatedly treated patients].
Vnitrni lekarstvi 20040601
-
[Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
Vnitrni lekarstvi 20040601
-
Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing.
The Lancet. Oncology 20040501
-
Cardiotoxicity of cytotoxic drugs.
Cancer treatment reviews 20040401
-
Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Journal of inorganic biochemistry 20040401
-
Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions.
Allergy 20040201
-
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
Journal of cancer research and clinical oncology 20040101
-
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.
Cancer chemotherapy and pharmacology 20040101
-
The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.
Clinical and experimental immunology 20040101
-
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
BMC pharmacology 20040101
-
Iron chelators in cancer chemotherapy.
Current topics in medicinal chemistry 20040101
-
Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo.
BMC pharmacology 20040101
-
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.
Free radical biology & medicine 20031201
-
Supportive care of the older cancer patient.
Critical reviews in oncology/hematology 20031015
-
The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Molecular pharmacology 20030901
-
Protein profiling in daunorubicin-induced cardiomyopathy.
General physiology and biophysics 20030901
-
Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Biochemistry 20030819
-
Dexrazoxane does not protect against doxorubicin-induced damage in young rats.
American journal of physiology. Heart and circulatory physiology 20030801
-
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Cancer chemotherapy and pharmacology 20030801
-
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Bone marrow transplantation 20030801
-
Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines.
Leukemia research 20030701
-
Iron chelator research: past, present, and future.
Current medicinal chemistry 20030601
-
Cardiac toxicity of antineoplastic anthracyclines.
Current medicinal chemistry. Anti-cancer agents 20030301
-
Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats.
Cancer chemotherapy and pharmacology 20030201
-
Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy.
Angiology 20030101
-
Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Scandinavian journal of plastic and reconstructive surgery and hand surgery 20030101
-
Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Cardiovascular toxicology 20030101
-
Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression.
BMC pharmacology 20030101
-
Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187).
Drug metabolism and disposition: the biological fate of chemicals 20021201
-
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Cancer chemotherapy and pharmacology 20021201
-
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
Free radical biology & medicine 20020715
-
Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects.
Arteriosclerosis, thrombosis, and vascular biology 20020701
-
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Breast cancer research and treatment 20020701
-
[Cardiac toxicity in cancer therapy].
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20020701
-
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
British journal of cancer 20020605
-
Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin.
Leukemia 20020501
-
Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
British journal of pharmacology 20020401
-
Gateways to Clinical Trials.
Methods and findings in experimental and clinical pharmacology 20020401
-
The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
Anti-cancer drugs 20020301
-
Troponins in experimental studies.
Acta medica (Hradec Kralove) 20020101
-
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Cardiovascular toxicology 20020101
-
Multiple myeloma and its treatment.
Clinical journal of oncology nursing 20020101
-
Minimising the long-term adverse effects of childhood leukaemia therapy.
Drug safety 20020101
-
Effect of sodium 2,3-dimercaptopropane-1-sulphonate (DMPS) on chronic daunorubicin toxicity in rabbits: comparison with dexrazoxane.
Acta medica (Hradec Kralove) 20020101
-
Recent advances in the prevention of anthracycline cardiotoxicity in childhood.
Current medicinal chemistry 20011101
-
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
Lung cancer (Amsterdam, Netherlands) 20011101
-
Cytotoxic signalling by inhibitors of DNA topoisomerase II.
Biochemical Society transactions 20011101
-
In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
Leukemia 20011001
-
In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
Clinical cancer research : an official journal of the American Association for Cancer Research 20011001
-
The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Cancer chemotherapy and pharmacology 20011001
-
The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivity.
Cytotechnology 20011001
-
Anthracycline-induced cardiomyopathy.
Seminars in oncology 20010801
-
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 20010601
-
Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
Canadian journal of physiology and pharmacology 20010601
-
Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
British journal of cancer 20010401
-
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
Molecular pharmacology 20010301
-
Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Annals of oncology : official journal of the European Society for Medical Oncology 20010301
-
[Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
Voprosy onkologii 20010101
-
Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Neoplasma 20010101
-
A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Acta oncologica (Stockholm, Sweden) 20010101
-
Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo.
Toxicologic pathology 20010101
-
[Exercise tolerance in patients after acute lymphoblastic leukemia treatment in childhood].
Wiadomosci lekarskie (Warsaw, Poland : 1960) 20010101
-
Cardiovascular considerations with anthracycline use in patients with cancer.
Heart disease (Hagerstown, Md.) 20010101
-
Dexrazoxane (ICRF-187).
General pharmacology 19990101